Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis

Alcon Research215 enrolled

Overview

The purpose of this study is to evaluate patient perceptions of olopatadine 0.2% dosed once daily in patients previously treated with twice-daily, topical, ocular, anti-allergy medications.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

215

Conditions

Allergic Conjunctivitis

Interventions

Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)DRUG

Commercially marketed ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis

Eligibility

Sex: ALLMin age: 12 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 12 years of age or older. * History (within the past 24 months) of allergic conjunctivitis. * Active signs and symptoms of ocular allergies. * Ocular health within normal limits, as determined by the investigator or subinvestigator. * Willing to avoid contact lens wear each study visit immediately prior to study medication instillation and for 10 minutes after instillation of study drug. * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Contraindications or hypersensitivity to study medication or its components. * One sighted eye or not correctable to 0.6 logMAR or better in both eyes at the screening visit. * Known history of recurrent corneal erosion syndrome. * Ocular trauma or surgical intervention within 6 months prior to Visit 1. * Participation in any other investigational study within 30 days before Visit 1. * Pregnant or nursing. * Other protocol-defined exclusion criteria may apply.

Outcomes

Primary Outcomes

Overall Patient Satisfaction

Overall satisfaction was assessed by the patient on a questionnaire. The patient was instructed to select a single response to the statement, "Overall, how satisfied are you with your current eye allergy medication?" A 5-point scale was used: very satisfied, satisfied, undecided, dissatisfied, very dissatisfied. Results are reported as the percentage of patients who responded, "very satisfied" or "satisfied."

Time frame: Day 0

Overall Patient Satisfaction

Overall satisfaction was assessed by the patient on a questionnaire. The patient was instructed to select a single response to the statement, "Overall, how satisfied were you with olopatadine 0.2%?" A 5-point scale was used: very satisfied, satisfied, undecided, dissatisfied, very dissatisfied. Results are reported as the percentage of patients who responded, "very satisfied" or "satisfied."

Time frame: Day 7

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.